Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions
Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Anti-IgE treatment for severe allergic asthma has been available for more than seven years now. This treatment has clear clinical benefits and a good safety record. However, important questions concerning long-term dosing and treatment duration remain unanswered. This paper discusses the available information concerning the long-term use of omalizu...
Alternative Titles
Full title
Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_karger_primary_360771
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_karger_primary_360771
Other Identifiers
ISSN
0025-7931
E-ISSN
1423-0356
DOI
10.1159/000360771
